WebFeb 18, 2024 · Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M Seeking Alpha 42d Atara transfers rights for Ebvallo to Pierre Fabre in EU, certain other markets WebMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical …

Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy

WebNov 12, 2024 · ABSTRACT. Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body’s mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors.For this reason, MSLN has emerged as an important target for the development of novel immunotherapies. This review focuses on … WebNov 5, 2014 · Regional administration of MSLN CAR-transduced T cells results in superior antitumor efficacy (A) MSLN-targeted constructs with CD3ζ endodomain alone (Mz) or with the CD28 costimulatory domain (M28z). A PSMA-directed CAR with CD28 costimulation (P28z) as well as PSMA+-expressing EL4 targets are included in experiments as … burrow mcl

Early Results Promising for Next-Generation CAR T-cell Therapy …

WebAug 17, 2024 · Mesothelin-targeted chimeric antigen receptor T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer. Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 … WebAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress (Businesswire) - "ATA2271 (Solid Tumors Over-Expressing Mesothelin): The ongoing Phase 1, Memorial Sloan Kettering Cancer Center (MSK)-conducted, and investigator led clinical study of autologous mesothelin chimeric antigen receptor (CAR) … WebMay 15, 2024 · “We look forward to advancing our next-generation CAR T program which includes ATA2271 and off-the-shelf, allogeneic MSLN-directed CAR T immunotherapy, ATA3271, and expanding the investigation of our technology in other mesothelin-expressing solid tumors,” said AJ Joshi, MD, Senior Vice President and Chief Medical Officer of … hamot central scheduling